Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kerl, K; Prins, C; Cerroni, L; French, LE.
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
BRIT J DERMATOL. 2006; 154(5): 988-991.
Doi: 10.1111/j.1365-2133.2006.07151.x
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Cerroni Lorenzo
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Denileukin diftitox (Ontak) is a fusion protein comprising a diphtheria toxin and an interleukin (IL)-2 moiety that specifically targets CD25 (IL-2 receptor)-positive tumour cells. We report a patient with rapidly progressive Epstein-Barr virus-positive nasal type extranodal natural killer/T-cell lymphoma (extranodal NKTCL), treated with a combination of denileukin diftitox (Ontak) and oral bexarotene (Targretin). A significant regression of the cutaneous tumours was observed already after the first cycle of denileukin diftitox and was maintained for a period of 5 months with monthly cycles of denileukin diftitox. The treatment was well tolerated. Following this response the patient decided to stop the treatment. He was then followed by his oncologist and lost from dermatological follow-up. Shortly after treatment withdrawal the disease progressed and the patient received one cycle of doxorubicin (Caelyx). He died from septic shock syndrome 2 months later. To our knowledge this is the first case of extranodal NKTCL treated with denileukin diftitox and bexarotene. A striking, albeit transient, response occurred with this therapy. Combination treatment with denileukin diftitox and bexarotene should be further assessed in this aggressive type of cutaneous lymphoma.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Diphtheria Toxin - administration and dosage
- Fatal Outcome - administration and dosage
- Humans - administration and dosage
- Interleukin-2 - administration and dosage
- Killer Cells, Natural - pathology
- Lymphoma, T-Cell, Cutaneous - drug therapy
- Male - drug therapy
- Middle Aged - drug therapy
- Recombinant Fusion Proteins - administration and dosage
- Skin Neoplasms - drug therapy
- Tetrahydronaphthalenes - administration and dosage
- Find related publications in this database (Keywords)
- bexarotene
- cutaneous T-cell lymphoma
- denileukin diftitox
- natural killer lymphoma